1	Performance drift is a major barrier to the safe use of
2	machine learning in cardiac surgery
3	Tim Dong MSc <sup>1</sup> , Shubhra Sinha MBBS <sup>1</sup> , Ben Zhai PhD <sup>3</sup> , Daniel P Fudulu, PhD <sup>1</sup> , Jeremy Chan
4	MD <sup>1</sup> , Pradeep Narayan, FRCS(CTh) <sup>2</sup> , Andy Judge PhD <sup>1</sup> , Massimo Caputo MD <sup>1</sup> , Arnaldo
5	Dimagli MD <sup>1</sup> , Umberto Benedetto PhD <sup>1</sup> and Gianni D. Angelini MD <sup>1</sup> .
6	
7	
8	<sup>1</sup> Bristol Heart Institute, Translational Health Sciences, University of Bristol
9	<sup>2</sup> Departement of Cardiac Surgery, Rabindranath Tagore International Institute of Cardiac
10	Sciences, India
11	<sup>3</sup> School of Computing Science, Newcastle University
12	
13	
14	Corresponding Author:
15	Prof Gianni Angelini MD,
16	British Heart Foundation Professor of Cardiac Surgery
17	Level 7,
18	Bristol Heart Institute,
19	Bristol,
20	BS2 8HW.
21	Phone number: +441173423165
22	Email: <u>G.D.Angelini@bristol.ac.uk</u>
23	

# 24 ABSTRACT

25	Objectives The Society of Thoracic Surgeons (STS), and EuroSCORE II (ES II) risk scores,
26	are the most commonly used risk prediction models for adult cardiac surgery post-operative
27	in-hospital mortality. However, they are prone to miscalibration over time, and poor
28	generalisation across datasets and their use remain controversial. It has been suggested that
29	using Machine Learning (ML) techniques, a branch of Artificial intelligence (AI), may
30	improve the accuracy of risk prediction. Despite increased interest, a gap in understanding the
31	effect of dataset drift on the performance of ML over time remains a barrier to its wider use
32	in clinical practice. Dataset drift occurs when a machine learning system underperforms
33	because of a mismatch between the dataset it was developed and the data on which it is
34	deployed. Here we analyse this potential concern in a large United Kingdom (UK) database.
35	Methods: A retrospective analyses of prospectively routinely gathered data on adult patients
36	undergoing cardiac surgery in the UK between 2012-2019. We temporally split the data
37	70:30 into a training and validation subset. ES II and five ML mortality prediction models
38	were assessed for relationships between and within variable importance drift, performance
39	drift and actual dataset drift using temporal and non-temporal invariant consensus scoring,
40	combining geometric average results of all metrics as the Clinical Effective Metric (CEM).
41	<b>Results:</b> A total of 227,087 adults underwent cardiac surgery during the study period with a
42	mortality rate of 2.76%. There was a strong evidence of decrease in overall performance
43	across all models (p < 0.0001). Xgboost (CEM 0.728 95CI: 0.728-0.729) and Random Forest
44	(CEM 0.727 95CI 0.727-0.728) were the best overall performing models both temporally and
45	non-temporally. ES II perfomed worst across all comparisons. Sharp changes in variable
46	importance and dataset drift between 2017-10 to 2017-12, 2018-06 to 2018-07 and 2018-12
47	to 2019-02 mirrored effects of performance decrease across models.

48	Conclusions: Combining the metrics covering all four aspects of discrimination, calibration,
49	clinical usefulness and overall accuracy into a single consensus metric improved the
50	efficiency of cognitive decision-making. All models show a decrease in at least 3 of the 5
51	individual metrics. CEM and variable importance drift detection demonstrate the limitation
52	of logistic regression methods used for cardiac surgery risk prediction and the effects of
53	dataset drift. Future work will be required to determine the interplay between ML and
54	whether ensemble models could take advantage of their respective performance
55	advantages.
56	Key words: cardiac surgery; artificial intelligence; risk prediction; machine learning;
57	operative mortality; dataset drift; performance drift; national dataset
58	
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	

- 70
- 71 Abbreviations and Acronyms:
- 72 AUC area under receiver operating characteristic curve;
- 73 CEM Clinical Effective Metric;
- 74 ECE Expected Calibration Error;
- 75 ES II Euroscore II;
- 76 Al Artificial intelligence;
- 77 ML machine learning;
- 78 RF random forest;
- 79 NN Neural Network (Neuronetwork);
- 80 SVM support vector machine;
- 81 XGBoost extreme gradient boosted trees
- 82 Ensemble using several models to derive a consensus prediction
- 83 SHAP (SHapley Additive exPlanations)
- 84
- 85
- 86
- 87

88

89	Central message: ML performance decreases over time due to dataset drift, but remains
90	superior to ES II. Therefore regular assessment and modification of ML models may be
91	preferable.
92	Prospective message: A gap in understanding the effect of dataset drift on the performance
93	of ML models over time presents a major barrier to their clinical application. Xgboost and
94	Random Forest have shown superior performance both temporally and non-temporally
95	against ES II. However, a decrease in model performance of all models due to dataset drift
96	suggests the need for regular drift monitoring.
97	
98	
99	
100	
101	
102	
103	
104	
105	
106	
107	

108

# 109 Introduction

110	Recently, the importance of Machine Learning (ML), a branch of Artificial intelligence (AI)
111	has been highlighted as a potential alternative to conventional mortality risk stratification
112	models such as Society of Thoracic Surgeons (STS),[1] and EuroSCORE II (ES II) risk scores,[2]
113	which are prone to miscalibration overtime and poor generalisation across datasets.[1,3] In
114	particular, the ES II, which is based on logistic regression using 18 items of information
115	about the patient, has been shown by numerous studies to display poor discrimination and
116	calibration across datasets with differing characteristics, including but not limited to age,[4]
117	ethnicity[5] and procedures groups.[6–10]
118	Risk scoring models' performance are challenged by numerous factors, such as
119	differences in variable definitions, management of incomplete data fields, surgical procedure
120	selection criteria, and temporal changes in the prevalence of patients' risk factors.[11] ML
121	approaches are increasingly used for prediction in health care research as they have the
122	potential to overcome limitations of linear models. By including pairwise and higher-order
123	interactions and modelling nonlinear effects ML may overcome heterogeneity in procedures
124	and missing data.[1,12] Whilst ML has been shown to be beneficial over conventional
125	scoring systems, the magnitude and clinical influence of such improvements remain
126	uncertain.[2] The ability to counter "performance drift" due to temporal changes in the
127	prevalence of risk factors has also yet to be fully elucidated.
128	We envisaged that different Machine learning models may perform better for
129	different metrics and that providing a panel of metrics would be important for covering the

130 multifaceted aspects of clinical model performance. The Miller's law observed that the

131	human working memory is limited to holding on to an average of seven items in the short-
132	term memory.[13] This is particularly relevant in a scenario where a clinician would need to
133	select from a number of ML models based on a panel of performance metrics. The split-
134	attention effect cognition theory indicates that a single integrated source of information
135	enhances knowledge acquisition better than separated sources of information.[14]
136	Therefore, we a consensus approach to metric evaluation by combining the five
137	performance metrics for risk stratification.
138	We therefore, trained and evaluated 5 supervised ML models to: (1) determine the
138 139	We therefore, trained and evaluated 5 supervised ML models to: (1) determine the best ML model in terms of overall accuracy, discrimination, calibration and clinical
138 139 140	We therefore, trained and evaluated 5 supervised ML models to: (1) determine the best ML model in terms of overall accuracy, discrimination, calibration and clinical effectiveness, (2) use variable importance drift as a measure for detecting dataset drift and
138 139 140 141	We therefore, trained and evaluated 5 supervised ML models to: (1) determine the best ML model in terms of overall accuracy, discrimination, calibration and clinical effectiveness, (2) use variable importance drift as a measure for detecting dataset drift and (3) verify suspected dataset drift by assessing the relationship between and within
138 139 140 141 142	We therefore, trained and evaluated 5 supervised ML models to: (1) determine the best ML model in terms of overall accuracy, discrimination, calibration and clinical effectiveness, (2) use variable importance drift as a measure for detecting dataset drift and (3) verify suspected dataset drift by assessing the relationship between and within performance drift, variable importance drift and dataset drift (e.g. due to changing case-

### 144 Methods

### 145 **Dataset and Patient Population**

- 146 The study was performed using the National Adult Cardiac Surgery Audit (NACSA) dataset,
- 147 which comprises data prospectively collected by National Institute for Cardiovascular
- 148 Outcome Research on all cardiac procedures performed in all NHS hospitals and some
- 149 private hospitals across the UK.[17]
- 150 Patients undergoing cardiac surgery between 1 Jan 2012 and 31 Mar 2019 were
- included. Missing and erroneously inputted data in the dataset were cleaned according to
- the National Adult Cardiac Surgery Audit Registry Data Pre-processing recommendations.[18]
- 153 Generally, for any variable data that were missing, it was assumed that the variable was at

154	baseline level, i.e., no risk factor was present. Missing patient age at the time of surgery was
155	imputed as the median patient age for the corresponding year. Data standardization was
156	performed by subtracting the variable mean and dividing by the standard deviation
157	values.[19]
158	The dataset was split into two cohorts: Training/Validation (n = 157196; 2012-2016;
159	Table S1) and Holdout (n = 69891; 2017-2019; Table S2). The primary outcome of this study
160	was in-hospital mortality.
161	The study was part of a research project approved by the Health Research Authority
162	(HRA) and Health and Care Research Wales. As the study included retrospective
163	interrogation of the NICOR database, the need for individual patient consent was waived
164	(HCRW) (IRAS ID: 278171) in accordance with the research guidance. The study was
165	performed in accordance with the ethical standards as laid down in the 1964 Declaration of
166	Helsinki and its later amendments.
167	
168	Baseline Statistical analysis
169	Continuous variables are compared using non-parametric Wilcoxon rank-sum tests, whilst
170	categorical variables are compared using Pearson's $\chi^2$ tests or Fisher's exact tests as
171	appropriate.
172	Scikit-learn v0.23.1 and Keras v2.4.0 were used to develop the models and to evaluate their
173	discrimination, calibration and clinical effectiveness capabilities. Statistical analyses are
174	conducted using STATA-MP version 17 and R v4.0.2.[20] Anova Assumptions were checked
175	using R rstatix package.

# 176 Model Development

177	In our study, we trained five supervised ML risk models based on the ES II preoperative
178	variable set (Table S3). Those five models included Logistic Regression, Neural Network
179	(Neuronetwork / NN),[19] Random Forest (RF),[21] Weighted Support Vector Machine
180	(SVM),[22] and Xgboost[23].[17] ES II score was calculated for baseline comparison. Internal
181	validation was performed using fivefold cross-validation on the Training/Validation dataset
182	(2012-2016). External validation was performed on the Holdout dataset (2017-2019).[16]
183	Each model calculated the probability of surgical mortality for each patient. One thousand
184	bootstrap samples were taken for all metrics. Further details on model development can be
185	found in Supplementary Materials, section: Model Specification.

186

197

# 187 Assessment of model performance

188	The Area Under the Curve (AUC) performances of all variant models were evaluated, and
189	the ROC curves plotted.[24] As a sensitivity analysis, we excluded the True Negative Rate
190	from the performance evaluation, by calculating the $F_1$ score.[25] This metric adjusts for the
191	biased effect due to high proportion of alive outcome samples. Decision Curve net benefit
192	index is used to test clinical benefit.[26] 1 - Expected Calibration Error (ECE) was used to
193	determine calibration performance, with higher values being better.[27] The adjusted Brier
194	score (1 – Brier) was used without the normalization term,[28] but with higher values
195	indicating better discrimination and calibration performance.
196	To determine the best model in terms of both discrimination and calibration, we

took the geometric average of AUC, F1,[25] Decision Curve net benefit (Treated +

- 198 Untreated), 1 ECE and 1 Brier. Geometric average has previously been found to be
- 199 effective for summarising metrics for temporal based model calibration[29]. This metric is
- robust to outliers, [30] and is preferable for aggregation compared to the weighted
- 201 geometric mean.[31] The arithmetic average was used for Decision Curve net benefit over
- all thresholds as a measure of overall net benefit, before geometric averaging, since values
- 203 can be negative. We proposed a new metric using the combined geometric average results
- of all metrics, named Clinical Effective Metric (CEM). An overview of the model and
- 205 evaluation design is shown in Figure 1.

Figure 1. Design overview of the study; non-temporal performance and drift (temporal) analyses are
 performed; drift in discrimination, calibration, clinical utility, dataset and variable importance are
 assessed; time point assessments are performed for CEM; drifts in component metrics of CEM are
 evaluated.



210 211

### 212 Baseline non-temporal performance

213 Non-temporal comparison of models was conducted as a baseline, using all data across the

Holdout period. Differences across models were tested using repeated measures One-Way

- Anova and Bonferroni Corrected multiple pairwise paired t-tests; this was followed by
- 216 Dunnett's Correction for multiple comparisons, with the best overall performing model as
- 217 control. ANOVA assumptions for outliers were checked. Normality assumptions were
- checked using the Shapiro-Wilk test.[32]
- 219

### 220 Drift Analysis

- 221 CEM Regression trends
- 222 Geometric CEM mean of 1000 bootstraps for each model against month of the year was
- calculated as well as 95% CI and the results were plotted to compare trends across models.
- The models were compared by fitting multiple linear regression lines across year months for
- 225 CEM.
- To check for normality assumptions, we plotted the histogram and a QQ plot of
- residuals before applying linear regression.[33] We also checked for homogeneity of
- residual variance (homoscedasticity) by plotting a scale-location plot i.e. the square root of
- standardised residual points against values of the fitted outcome variable.[34] For model
- 230 metrics that do not satisfy these assumptions, the Seasonall Kendall Test (non-parametric)
- was used instead.

### 232 Analysis within first 3 months of 2017 and 2019

- 233 Differences in CEM across models at two time-points were independently tested using
- 234 Kruskal-Wallis Test and Bonferroni Corrected paired samples Wilcoxon test (Wilcoxon
- signed-rank test). The two time-points were the first three months of 2017 and 2019,
- respectively. This was followed by the Dunn test for non-parametric multiple comparisons of

- 237 models at each of the two-time points, with the best overall performing model as a baseline.
- 238 ANOVA assumptions for outliers were checked. Normality assumptions were checked using
- the Shapiro-Wilk test.[32]
- Analysis between first 3 months of 2017 and 2019
- 241 Differences in models' CEM across the first three months of 2017 and 2019 were tested
- using Kruskal-Wallis Test and paired samples Wilcoxon test (Wilcoxon signed-rank test).
- 243 Dunn test was used to determine the magnitude and evidence of change across the two-
- time points for each model. ANOVA assumptions for outliers were checked. Normality
- assumptions were checked using Kolmogorov-Smirnov Test.
- 246 Analysis of discrimination, calibration, clinical utility and overall accuracy drift
- As a sensitivity analysis, we analysed performance drift in terms of component metrics
- within CEM. Discrimination (AUC), positive outcome discrimination (F1 score), calibration (1
- 249 ECE), clinical utility (net benefit), Adjusted Brier score (overall accuracy of prediction
- 250 probability) were assessed by fitting multiple (model) linear regression lines across year
- 251 month for each metric, respectively.
- To check for normality assumptions, we plotted the histogram and a QQ plot of
- residuals before applying linear regression.[33] We also checked for homogeneity of
- residual variance (homoscedasticity) by plotting a scale-location plot i.e. the square root of
- standardised residual points against values of the fitted outcome variable.[34] For model
- 256 metrics that do not satisfy these assumptions, the Seasonall Kendall Test (non-parametric) is
- 257 used instead.

## 258 Analysis of variable importance drift

259	Variable importance drift was assessed for the best performing model. For each year month
260	of the Holdout dataset, 5-fold nested cross-validation was performed to derive importance
261	of each ES II variable in the model's decision making. The geometric mean of 5-fold
262	importance at each time point was plotted along with the importance of each of the 5 folds.
263	The SHAP mean absolute magnitude of importance was used.[35,36] Loess smoothing was
264	used to simplify the visual representation. Line plots of the top six important variables were
265	used as sensitivity analysis.
266	Dataset drift
267	Dataset drift across year month was visualised using a stacked bar plot for the top three
268	variables as identified by SHAP variable importance. Continuous variables were binned into
269	intervals to enable ease of analysis.
270	
271	Results
272	Baseline patient characteristics
273	A total of 227,087 procedures of adults from 42 hospitals were included in this analysis. This

followed the removal of 3,930 congenital cases, 1,586 transplant and mechanical support

device insertion cases and 3,395 procedures missing information on mortality (Table 1).

There were 6,258 deaths during the study period (mortality rate of 2.76%).

277

278 Baseline non-temporal performance

279	No extreme outliers were found. The CEM scores were normally distributed for all three
280	models except Xgboost, as assessed by Shapiro-Wilk's test (p > 0.05). A histogram plot of the
281	Xgboost CEM values did not show substantial deviation from the normal distribution. There
282	was strong evidence of a difference across all models p < 0.0001 (Table S4 and Figure S1).
283	Table 2 shows that Xgboost (CEM 0.728 95CI (95% confidence interval): 0.728-0.729) and RF
284	(CEM 0.727 95CI 0.727-0.728) are the best overall performing models, with moderate to
285	strong evidence (non-overlapping CI) of the former outperforming the latter. This was
286	followed by LR, NN, SVM then ES II. Dunnett's test showed that there was moderate to
287	strong evidence that Xgboost was superior to all other models (p < 0.001) (Table 3). Xgboost
288	performance was least different from RF, but most different from ES II (CEM difference
289	0.0009 vs. 0.1876).
290	Sensitivity analysis of CEM component metrics shows that the adjusted Brier score
291	was unable to distinguish Xgboost, RF, NN and LR (Table 2, all 0.976). AUC performance was
292	best for Xgboost (0.834) and RF (0.835). F1 score showed that Xgboost performed best
293	followed by RF (0.279 vs. 0.277). LR and NN (adjusted ECE: both 0.997) showed better
294	calibration performance than RF and Xgboost (adjusted ECE: both 0.996). Net Benefit overall
295	was best for Xgboost and RF (both 0.904).

296 Drift Analysis

# 297 Overall CEM

Figure 2. a) Plot of CEM by model and by year month; geometric mean of 1000 bootstraps at each time point is shown as is 95% CI; horizontal line represents the CEM geometric mean of all models; b) Box plot of difference in models' CEM across first three months of 2017 and 2019; Kruskal-Wallis results for CEM across the time points are shown; c) Paired samples Wilcoxon test (Wilcoxon signed-rank test) for first 3 months of 2019 bootstrap CEM values; p-values are adjusted using the bonferroni method.

303



305

Figure 2a shows that Xgboost and RF were candidates for the best overall CEM performance 306 307 across year month. There was minor evidence of LR outperforming NN across time. Seasonal 308 fluctuations were observed. ES II performed worst across time followed by SVM.



- 312 0.000720) was less than NN (slope: -0.00083) and greater than RF (-0.000685) and LR (-
- 313 0.000696; Figure 3a-c and Figure S2.1).

314 Figure 3. Plot of CEM by model (a. Xgboost; b. Random Forest; c. Logistic Regression; d. EuroSCORE II) and 315 by year month; geometric mean of 1000 bootstraps at each time point is shown; red dotted line shows 316 linear regression; blue line shows Generalised Additive Model fit (GAM); parameters and p-value for 317 linear regression are shown; e) Discrimination (AUC) performance drift by year month; linear regression 318 lines are plotted for each model with slope, intercept and p-values displayed in legend; f) Calibration 319 (adjusted ECE) performance drift by year month; linear regression lines are plotted for each model with 320 slope, intercept and p-values displayed in legend; SVM and ES || are removed to enable clearer separation 321 of models with similar performance.



323

324

- 325 By March 2019, the overall CEM performance ranking was not changed, with Xgboost
- performing best, followed by RF, LR and then NN. ES II (intercept: 0.484, slope:- 0.000847)
- 327 performed worst in terms of starting CEM and rate of performance decrease, followed by
- 328 SVM (intercept:0.658; slope: -0.000625; Figure 3d and S2.2). Normality and homogeneity
- assumptions were satisfied for all model CEM values as checked by QQ plot of residuals and
- 330 scale-location plot (Supplementary Materials, Figure S2.3).

### 331 Analysis within first 3 months of 2017

- 332 No extreme outliers were found for models' CEM values in the first three month of 2017.
- The CEM scores were non-normally distributed for all models(p < 0.05). There was strong
- evidence of a difference across all models (p < 0.0001; Table 2b and Figure S3). Dunn test
- 335 showed strong evidence of Xgboost having the best overall performance (Table S6, p <
- 336 0.0001), followed by RF, NN and then LR (CEM difference to Xgboost: -0.0076, -0.0124 and -
- 337 0.0138, p < 0.0001). EuroSCORE II performed worst followed by Weighted SVM (CEM
- 338 difference to Xgboost: -0.2739, -0.0961, p < 0.0001).

### 339 <u>Analysis within the first 3 months of 2019</u>

- No extreme outliers were found for models' CEM values in the first three month of 2019.
- 341 The CEM scores were non-normally distributed for 50% of models(p < 0.05). There was
- strong evidence of a difference across all models (p < 0.0001; Table S7 and Figure 2b). Dunn
- 343 test showed strong evidence of Xgboost having the best overall performance (Table S8, p <
- 344 0.05), followed by RF, LR and then NN (CEM difference to Xgboost: -0.0032, -0.0055 and -

345 0.0108, p < 0.05). EuroSCORE II performed worst followed by Weighted SVM (CEM

- 346 difference to Xgboost: -0.2594, -0.0856, p < 0.0001).
- 347 <u>Analysis between first 3 months of 2017 and 2019</u>

348	No extreme outliers were found for models' CEM values in the first three months of 2017
349	and 2019. The CEM scores were non-normally distributed for the first 3 months of 2017 and
350	2019, as assessed by Kolmogorov-Smirnov Test (p < 0.05). There was strong evidence of an
351	overall difference across the two-time points (p < 0.0001; Table S9 and Figure S4). There was
352	strong evidence of a difference across the two-time points for each individual model (p <
353	0.05; Figure 2c and Table S10). Xgboost retained the best overall performance across the
354	time points examined. This model showed the largest decrease in CEM performance
355	(Median difference: 0.0288, p < 0.0001), followed by NN, RF and then LR (Median difference:
356	0.0272, 0.0244, 0.0205, p < 0.0001). Following a performance decrease from 2017 to 2019,
357	Xgboost still had the best overall performance with RF being second best (Median CEM
358	0.716, 0.713) Although NN had better starting performance than LR, the larger performance
359	drift resulted in NN having a lower overall performance than LR at 2019 (0.705 vs. 0.710).
360	However, although performance drift was smaller, LR's CEM performance never exceeded
361	RF (0.710 vs. 0.713). EuroSCORE II showed the least performance drift followed by Weighted
362	SVM (Median difference: 0.0142, 0.0183, $p < 0.05$ ), but both performed worst in terms of
363	absolute CEM.

364 <u>Analysis of discrimination, calibration and clinical effectiveness drift</u>

365 Discrimination

366 **AUC** 

367	Linear regression plots show that Xgboost has the best starting AUC (intercept = 0.843 vs.
368	0.839 (RF), 0.831 (LR, NN, SVM)), but rate of performance decrease was greater than RF and
369	ES II (slope: -0.000678 vs0.000381, -0.000604; Figure 3e). By March 2019, Xgboost AUC
370	had decreased below RF, resulting in RF being the best performing model, followed by
371	Xgboost, SVM, LR and then NN. NN showed the largest rate of AUC decrease followed by LR
372	and SVM (slope: -0.0014, -0.00093, -0.000873). ES II performed worst in terms of AUC across
373	all time points (intercept: 0.766). There was a strong evidence of decrease in AUC
374	performance across all models (p < 0.0001). Normality and homogeneity assumptionswere
375	satisfied for all model AUC values as checked by QQ plot of residuals and scale-location plot
376	(Figure S5).

#### 377 F1 score

378 The best performing model across all Holdout time periods was Xgboost, followed by RF, LR,

379 NN, SVM and then ES II. There was strong evidence of a decrease in F1 performance across

all models (p < 0.0001). For more details, see Supplementary Materials, section: Positive

381 outcome discrimination.

#### 382 Calibration

383 Linear regression plots showed that NN has the best starting adjusted ECE (intercept =

384 0.9907 vs. 0.9903 (RF), 0.9902 (Xgboost), 0.9898 (LR) ) but rate of performance decrease

385 was greater than LR and RF (slope: -5.29e-5 vs. -2.93e-6, -4.58e-5; Figure 3f). By March 2019,

386 NN adjusted ECE had decreased below LR, resulting in LR being the best performing model,

387 followed by NN, RF and then Xgboost. While SVM and ES II had lower rates of adjusted ECE

388 decrease (slope: -0.000251, -0.000479), the calibration performance was much lower at all

389 time points compared to the other models (Figure S6). There was strong evidence of

# 380

- decrease in adjusted ECE performance across all models (p < 0.0001), except LR (p > 0.05).
- 391 Normality and homogeneity assumptions were satisfied for all model adjusted ECE values as
- 392 checked by QQ plot of residuals and scale-location plot (Figure S7).

### 393 Clinical Effectiveness

394 Linear regression plots showed that Xgboost has the best starting net benefit (intercept =

395 0.9051 vs. 0.9043 (RF), 0.9035 (NN, LR)) but rate of performance decrease was greater than

- 396 RF (slope: -5.68e-5 vs. -2.5e-6; Figure 4a), but slower than LR (-9.38e-5) and even slower
- 397 than NN (-0.000145).

**Figure 4** a) Clinical effectiveness (net benefit) performance drift by year month; linear regression

399 lines are plotted for each model with slope, intercept and p-values displayed in legend; SVM and

ES II are removed to enable clearer separation of models with similar performance; b) SHAP

401 variable importance drift for 27 month of Holdout set; solid dots show geometric mean values of

402 5 fold cross validation; smoothed loess lines are plotted, with green bands showing 95%

403 confidence intervals; c) SHAP variable importance drift for 27 month of Holdout set for top six

404 most important variables; trends are unsmoothed; d) Operative urgency dataset drift across year

405 month for Holdout set; percentages of each category are shown for each time point.





By March 2019, Xgboost net benefit had decreased below RF, resulting in RF being the best
performing model, followed by Xgboost, LR and NN. ES II showed the largest rate of net
benefit decrease and performed worst across all time points followed by SVM (intercept:
0.314, 0.690; slope: -0.000846, -0.000364; Figure S8). There was strong evidence of a
decrease in net benefit performance across all models (p < 0.0001), except RF (p > 0.05).
Normality and homogeneity assumptions were satisfied for all model net benefit values as
checked by QQ plot of residuals and scale-location plot (Figure S9).

### 415 <u>Accuracy of prediction probability</u>

- By March 2019, Xgboost was the best model followed by RF, LR and then NN. ES II
- 417 performed worst in terms of Adjusted Brier and rate of decrease, followed by SVM. There
- 418 was strong evidence of a decrease in Adjusted Brier performance across all models (p <
- 419 0.0001), except Xgboost and RF. For more details, see Supplementary Materials, section:
- 420 Accuracy of prediction probability.

### 421 <u>Analysis of variable importance drift</u>

- 422 SHAP mean absolute magnitude of importance was used to measure variable importance
- 423 drift for the best temporal and non-temporal model (Xgboost). Smoothed trend lines
- showed substantial drift in numerous variables, including the most important variables: age,
- 425 operative urgency, the weight of intervention, NYHA, renal impairment and previous cardiac
- 426 surgery (Figure 4b). Sensitivity analysis showed a substantial drift in variable importance
- 427 across the Holdout set for all six variables (Figure 4c). When compared with CEM
- 428 performance drop between 2017-10 to 2017-12 and between 2018-06 to 2018-07 (Figure 3
- 429 GAM line), it could be seen that the CEM decrease was mirrored by decreases in the
- 430 importance of the top variables: age and operative urgency at these time periods (Figure 4c).
- 431 A decrease in CEM performance in the three months of 2019 was likely to be at least partly
- 432 contributed to by the sudden rise in importance of the weight of intervention (Figure 3 and
- 433 Figure 4b, 4c).

# 434 Dataset drift across time

Dataset drift is observed throughout the Holdout time periods for operative urgency with
sharp drifts observed across all categories between 2017-11 (YYYY-MM) to 2017-12 and

- 437 between 2018-06 and 2018-07 (Figure 4d). Dataset drift was observed across the Holdout

time periods for patient age groups above and below 60 (Figure S15), with marked data
drifts observed between 2017-10 to 2017-11 and between 2018-07 to 2018-08. Dataset drift
was observed across the Holdout time periods for Weight of intervention (Figure S16). Sharp
dataset drifts were observed for the Single non-CABG and 3 procedures category between
2018-12 to 2019-02.

443

### 444 DISCUSSION

445 The main finding of the study was that Xgboost performed best followed by RF, LR and then 446 NN when all metrics are simultaneously considered, both temporally and non-temporally. 447 Furthermore, EuroSCORE II substantially underperformed against all ML models across all 448 comparisons and presents an urgent need to replace this score. By first combining all 449 metrics and then analysing the temporal drift of each metric individually, we were able to 450 determine the contribution of individual metrics to the overall performance drift of each 451 model. We found strong evidence that all models showed a decrease in at least 3 of the 5 452 individual metrics within CEM. This demonstrated the importance for clinicians and ML 453 governance teams to actively monitor the effects of dataset drift (as explained later) on "Big 454 Data" models that are prepared for or being clinically used in order to minimise the risk of 455 harm to patients.

"Big data" refers to large and detailed datasets that are suited to ML analyses rather
than traditional statistical analyses.[37,38] This is increasingly utilised in healthcare. These
analyses can inform, personalise and potentially improve care.[37,39,40] Despite growing
interest[41] in ML and healthcare data linkage initiatives such the Health Informatics
Collaborative (HIC),[42] there have been limited reports of usage within cardiac surgery,[43–

461 45] with one of the main reasons being a lack of understanding by clinicians of the

462 underlining processes.[46]

463	As more countries follow in the steps of the U.S. to deploy ML to the medical
464	settings,[47] it becomes increasingly critical that clinicians and ML governance teams are
465	adequately prepared for situations in which ML systems fail to perform their intended
466	functions.[48] A major factor in ML malfunction is "Dataset Drift", where ML performance
467	declines due to a mismatch between the data on which the model was trained and the new
468	unseen data to which the model is applied.[49] Several factors have been reported to
469	influence dataset drift, including changes in technology, demographics, and patient or
470	clinician behaviour.[48]
471	In our previous systematic review, we found that despite ML models achieving
472	better discriminatory ability than traditional LR approaches, few cardiac surgery studies

assessed calibration, clinical utility, discrimination and dataset drift collectively; these

aspects should be assessed to determine the clinical implications of ML.[2] While calibration

475 drift over time is well documented amongst EuroSCORE and logistic regression models for

476 hospital mortality, the susceptibility of competing ML modelling methods to dataset drift

477 has not been well studied in cardiac surgery.[50]

This study heeds to the call for additional metrics to address the lack of sensitivity of the most commonly used C-statistic and calibration slope in capturing the advantage of ML models, [51] by demonstrating the use of a consensus score [19,52–55] named CEM to take into account numerous metrics that have been found to be beneficial, covering overall accuracy, [51] discrimination, calibration and clinical utility. This study showed invariance in 483 model ranking for the CEM in both temporal and non-temporal analyses, indicating there is
484 value for this consensus scoring approach in performance drift evaluation.

The current study also addresses the gap in understanding the effect of dataset drift on the performance of ML and traditional models over time, which presents a barrier to their clinical application. The shift in best performing AUC and net benefit model between Xgboost and RF, and between NN and LR for "adjusted ECE" demonstrates that comparison of models at a single time point was insufficient to understand the clinical limitations of ML models and at least two-time points should be considered.

491 Our study has also found that although RF shows comparable discrimination (AUC) 492 and clinical utility (net benefit) performance across time, the reason for Xgboost's superior 493 overall temporal performance was in its better overall accuracy (Adjusted Brier) and positive 494 outcome discrimination (F1). F1 score is often overlooked, but is especially important in 495 cardiac surgery datasets, whereby the incidence for the outcome of interest is typically very 496 low and introduces bias in the performance evaluation, when AUC is used. We found that RF 497 performed second best overall. Unlike Xgboost, RF performed better in terms of resistance to drift in AUC and net benefit, suggesting that further work is required to determine 498 whether the synergistic (ensemble) effects across models are beneficial for improving 499 500 cardiac surgery risk prediction. Although Xgboost is currently the best temporal and non-501 temporal model for the National Adult Cardiac Surgery Audit dataset, periodic monitoring of 502 performance drift for each yearly revision of this dataset should be mandated to determine whether or not performance is overtaken by RF, and if so, at what point in time this 503 504 happens. [48] As all models showed strong evidence of decrease in overall performance

from 2017-01 to 2019-03, further work will be required to develop either better performing
models or models that are less susceptible to performance drift.

507	We have demonstrated that by associating relationships between smoothed[56] and
508	unsmoothed trend lines for CEM performance and ES II variable importance, that it was
509	possible to detect subtle dataset drifts that could result in model performance drifts. Our
510	findings of variable importance and dataset drift between 2017-10 to 2017-12, between
511	2018-06 to 2018-07 and between 2018-12 to 2019-02 are likely to reflect seasonality
512	changes and mirrored effects of sharp drifts in CEM performance across models. The
513	detection of dataset drift was verified by checking for actual drifts in the dataset variables. A
514	non-cardiac surgery study has used actual dataset drift to check for variable importance
515	detected dataset drift.[50] However, drift in the actual dataset was only analysed across two
516	data points,[50] without consideration for smoothed and unsmoothed relationships across
517	performance, variable importance and actual variable incidence. The current study provides
518	the foundations for which further work analysing ML performance drift are recommended
519	to analyse relationships between drifts in a consensus score such as CEM and in variable
520	importance, followed by confirmation of any detected drifts using actual dataset trends.

521

### 522 Limitations

Although statistical rigour has been applied to determine whether performance drift is a barrier to clinical risk modelling and decision-making, further work could be done to apply more statistically sensitive approaches to comparing the interactions of trends in dataset drift, performance drift and variable importance drift. While CEM is a consensus score that enhances clinical evaluation of complex relationships across different aspects of model

performance, compressing the net benefit measure into a single value would mean that
further decision curve analysis may be required if individual-specific threshold-based
decisions were to be fully considered.

531

### 532 CONCLUSION

533 This study addresses the gap in understanding the effect of dataset drift on the performance 534 of ML and traditional models over time, which presents a barrier to the clinical application

of ML. This was demonstrated by highlighting the importance of using a temporal and non-

536 temporal ranking invariant consensus-based score for evaluating various ML approaches

537 against traditional models, using smoothed and unsmoothed trend analysis, while

538 comparatively assessing for relationships between and within variable importance drift,

539 performance drift and actual dataset drift, for selecting the clinical ML model that minimizes

540 the risk of patient harm. The strong evidence of all models showing a decrease in at least 3

541 of the 5 individual metrics within CEM demonstrates the importance of clinicians and ML

542 governance teams actively monitoring the effects of dataset drift on models that are

543 prepared for or being used for cardiac surgery risk prediction. Our data suggest that

544 EuroSCORE II should be replaced with better performing ML models such as Xgboost and RF,

545 which have demonstrated less drift over time. Future work will be required to determine

the interplay between Xgboost and RF and whether ensemble models could take advantage

547 of their respective performance advantages.

548 **Acknowledgement**: This work was supported by a grant from the BHF-Turing Institute and

549 the NIHR Biomedical Research Centre at University Hospitals Bristol and Weston NHS Foundation

550 Trust and the University of Bristol.

### 551 Data availability

- 552 All data used in this study are from the National Adult Cardiac Surgery Audit (NACSA) dataset. These
- data may be requested from Healthcare Quality Improvement Partnership (HQIP),
- 554 https://www.hqip.org.uk/national-programmes/accessing-ncapop-data/#.Ys6gN-zMLdp.
- 555
- \_\_\_\_
- 556
- 557
- 558
- 559
- 560
- 561
- 562
- 563

564

504

565

# 566 References

567 1 Ong CS, Reinertsen E, Sun H, *et al.* Prediction of operative mortality for patients undergoing
 568 cardiac surgical procedures without established risk scores. *The Journal of Thoracic and* 569 *Cardiovascular Surgery* Published Online First: 14 September 2021.

- 570 doi:10.1016/j.jtcvs.2021.09.010
- 571 2 Benedetto U, Dimagli A, Sinha S, *et al.* Machine learning improves mortality risk prediction after
- 572 cardiac surgery: Systematic review and meta-analysis. *The Journal of Thoracic and Cardiovascular* 573 *Surgery* Published Online First: 10 August 2020. doi:10.1016/j.jtcvs.2020.07.105

Kieser TM, Rose MS, Head SJ. Comparison of logistic EuroSCORE and EuroSCORE II in predicting
 operative mortality of 1125 total arterial operations †. *European Journal of Cardio-Thoracic Surgery* 2016;**50**:509–18. doi:10.1093/ejcts/ezw072

- Poullis M, Pullan M, Chalmers J, *et al.* The validity of the original EuroSCORE and EuroSCORE II in
   patients over the age of seventy. *Interactive CardioVascular and Thoracic Surgery* 2015;**20**:172–7.
   doi:10.1093/icvts/ivu345
- 580 5 Zhang G, Wang C, Wang L, *et al.* Validation of EuroSCORE II in Chinese Patients Undergoing Heart
   581 Valve Surgery. *Heart, Lung and Circulation* 2013;**22**:606–11. doi:10.1016/j.hlc.2012.12.012

582 6 Silaschi M, Conradi L, Seiffert M, *et al.* Predicting Risk in Transcatheter Aortic Valve Implantation:
 583 Comparative Analysis of EuroSCORE II and Established Risk Stratification Tools. *Thorac Cardiovasc* 584 Surg 2015;**63**:472–8. doi:10.1055/s-0034-1389107

- 585 7 Carnero-Alcázar M, Silva Guisasola JA, Reguillo Lacruz FJ, *et al.* Validation of EuroSCORE II on a
   586 single-centre 3800 patient cohort. *Interactive CardioVascular and Thoracic Surgery* 2013;**16**:293–
   587 300. doi:10.1093/icvts/ivs480
- Arangalage D, Cimadevilla C, Alkhoder S, *et al.* Agreement between the new EuroSCORE II, the
  Logistic EuroSCORE and the Society of Thoracic Surgeons score: Implications for transcatheter
  aortic valve implantation. *Archives of Cardiovascular Diseases* 2014;**107**:353–60.
  doi:10.1016/j.acvd.2014.05.002
- 592 9 Atashi A, Amini S, Tashnizi MA, *et al.* External Validation of European System for Cardiac
  593 Operative Risk Evaluation II (EuroSCORE II) for Risk Prioritization in an Iranian Population. *Braz J*594 *Cardiovasc Surg* 2018;**33**:40–6. doi:10.21470/1678-9741-2017-0030
- 595 10 Provenchère S, Chevalier A, Ghodbane W, *et al.* Is the EuroSCORE II reliable to estimate
  596 operative mortality among octogenarians? *PLOS ONE* 2017;**12**:e0187056.
  597 doi:10.1371/journal.pone.0187056
- Nilsson J, Ohlsson M, Thulin L, *et al.* Risk factor identification and mortality prediction in
   cardiac surgery using artificial neural networks. *The Journal of Thoracic and Cardiovascular Surgery* 2006;**132**:12-19.e1. doi:10.1016/j.jtcvs.2005.12.055
- 60112Kurlansky P. Commentary: The risk of risk models. The Journal of Thoracic and602Cardiovascular Surgery 2020;160:181–2. doi:10.1016/j.jtcvs.2019.12.063
- Kang X. The Effect of Color on Short-term Memory in Information Visualization. In:
   *Proceedings of the 9th International Symposium on Visual Information Communication and Interaction*. Dallas TX USA: : ACM 2016. 144–5. doi:10.1145/2968220.2968237
- 60614Ayres P, Cierniak G. Split-Attention Effect. In: Seel NM, ed. Encyclopedia of the Sciences of607Learning. Boston, MA: : Springer US 2012. 3172–5. doi:10.1007/978-1-4419-1428-6\_19
- Benedetto U, Dimagli A, Gibbison B, *et al.* Disparity in clinical outcomes after cardiac surgery
  between private and public (NHS) payers in England. *The Lancet Regional Health Europe* 2021;1.
  doi:10.1016/j.lanepe.2020.100003
- Hickey GL, Blackstone EH. External model validation of binary clinical risk prediction models
   in cardiovascular and thoracic surgery. *The Journal of Thoracic and Cardiovascular Surgery* 2016;**152**:351–5. doi:10.1016/j.jtcvs.2016.04.023

614 17 Benedetto U, Sinha S, Lyon M, et al. Can machine learning improve mortality prediction 615 following cardiac surgery? European Journal of Cardio-Thoracic Surgery 2020;58:1130-6. 616 doi:10.1093/ejcts/ezaa229 617 18 Hickey GL, Grant SW, Cosgriff R, et al. Clinical registries: governance, management, analysis 618 and applications. European Journal of Cardio-Thoracic Surgery 2013;44:605-14. 619 doi:10.1093/ejcts/ezt018 620 19 Dong T, Benedetto U, Sinha S, et al. Deep recurrent reinforced learning model to compare 621 the efficacy of targeted local versus national measures on the spread of COVID-19 in the UK. BMJ 622 Open 2022;12:e048279. doi:10.1136/bmjopen-2020-048279 623 20 StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021. 624 21 Sarica A, Cerasa A, Quattrone A. Random Forest Algorithm for the Classification of 625 Neuroimaging Data in Alzheimer's Disease: A Systematic Review. Front Aging Neurosci 2017;9:329. 626 doi:10.3389/fnagi.2017.00329 627 22 Prabhakararao E, Dandapat S. A Weighted SVM Based Approach for Automatic Detection of 628 Posterior Myocardial Infarction Using VCG Signals. In: 2019 National Conference on 629 Communications (NCC). 2019. 1-6. doi:10.1109/NCC.2019.8732238 630 23 Rajliwall NS, Davey R, Chetty G. Cardiovascular Risk Prediction Based on XGBoost. In: 2018 631 5th Asia-Pacific World Congress on Computer Science and Engineering (APWC on CSE). 2018. 246-632 52. doi:10.1109/APWConCSE.2018.00047 633 24 Kumar NK, Sindhu GS, Prashanthi DK, et al. Analysis and Prediction of Cardio Vascular 634 Disease using Machine Learning Classifiers. In: 2020 6th International Conference on Advanced 635 Computing and Communication Systems (ICACCS). 2020. 15–21. 636 doi:10.1109/ICACCS48705.2020.9074183 637 25 Tiwari P, Colborn KL, Smith DE, et al. Assessment of a Machine Learning Model Applied to 638 Harmonized Electronic Health Record Data for the Prediction of Incident Atrial Fibrillation. JAMA 639 Network Open 2020;3:e1919396-e1919396. doi:10.1001/jamanetworkopen.2019.19396 640 26 Allyn J, Allou N, Augustin P, et al. A Comparison of a Machine Learning Model with 641 EuroSCORE II in Predicting Mortality after Elective Cardiac Surgery: A Decision Curve Analysis. 642 PLOS ONE 2017;12:e0169772. doi:10.1371/journal.pone.0169772 643 27 Mehrtash A, Wells WM, Tempany CM, et al. Confidence Calibration and Predictive 644 Uncertainty Estimation for Deep Medical Image Segmentation. IEEE Transactions on Medical 645 Imaging 2020;39:3868-78. doi:10.1109/TMI.2020.3006437 646 28 Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the Performance of Prediction Models: 647 A Framework for Traditional and Novel Measures. Epidemiology 2010;21:128-38. 648 doi:10.1097/EDE.0b013e3181c30fb2 649 Armstrong JS, Collopy F. Error measures for generalizing about forecasting methods: 29 650 Empirical comparisons. International Journal of Forecasting 1992;8:69-80. doi:10.1016/0169-

651 2070(92)90008-W

652 30 Kacalak W, Lipiński D, Różański R, et al. Assessment of the classification ability of parameters 653 characterizing surface topography formed in manufacturing and operation processes. 654 Measurement 2021;170:108715. doi:10.1016/j.measurement.2020.108715 655 31 Krejčí J. Stoklasa J. Aggregation in the analytic hierarchy process: Why weighted geometric 656 mean should be used instead of weighted arithmetic mean. Expert Systems with Applications 657 2018;114:97-106. doi:10.1016/j.eswa.2018.06.060 658 32 González-Estrada E, Cosmes W. Shapiro–Wilk test for skew normal distributions based on 659 data transformations. Journal of Statistical Computation and Simulation 2019;89:3258–72. 660 doi:10.1080/00949655.2019.1658763 661 33 US EPA O. Guidance for Data Quality Assessment. 2015.https://www.epa.gov/quality/guidance-data-quality-assessment (accessed 10 Feb 2022). 662 663 34 McLeod AI. Improved Spread-Location Visualization. Journal of Computational and Graphical 664 Statistics 1999;8:135-41. doi:10.1080/10618600.1999.10474806 665 35 Barda N, Riesel D, Akriv A, et al. Developing a COVID-19 mortality risk prediction model 666 when individual-level data are not available. Nat Commun 2020;11:4439. doi:10.1038/s41467-667 020-18297-9 668 36 Lundberg SM, Lee S-I. A Unified Approach to Interpreting Model Predictions. ::10. 669 37 Raghupathi W, Raghupathi V. Big data analytics in healthcare: promise and potential. Health 670 Inf Sci Syst 2014;2:3. doi:10.1186/2047-2501-2-3 671 38 Silverio A, Cavallo P, De Rosa R, et al. Big Health Data and Cardiovascular Diseases: A 672 Challenge for Research, an Opportunity for Clinical Care. Front Med (Lausanne) 2019;6:36. 673 doi:10.3389/fmed.2019.00036 674 39 Agrawal R, Prabakaran S. Big data in digital healthcare: lessons learnt and recommendations 675 for general practice. *Heredity* 2020;**124**:525–34. doi:10.1038/s41437-020-0303-2 676 40 Pencina MJ, Goldstein BA, D'Agostino RB. Prediction Models — Development, Evaluation, 677 and Clinical Application. New England Journal of Medicine 2020;382:1583-6. 678 doi:10.1056/NEJMp2000589 679 41 Ruiz VM, Goldsmith MP, Shi L, et al. Early prediction of clinical deterioration using data-680 driven machine-learning modeling of electronic health records. The Journal of Thoracic and 681 Cardiovascular Surgery 2021;0. doi:10.1016/j.jtcvs.2021.10.060 682 42 Sinha S, Benedetto U, Mulla A, et al. Abstract 14169: Implications of Elevated Troponin on 683 Time-to-Surgery in Non-ST Elevation Myocardial Infarction (NIHR Health Informatics Collaborative: Trop-CABG Study). Circulation 2021;144:A14169-A14169. doi:10.1161/circ.144.suppl\_1.14169 684 685 43 Hernandez-Suarez DF, Kim Y, Villablanca P, et al. Machine Learning Prediction Models for In-686 Hospital Mortality After Transcatheter Aortic Valve Replacement. JACC Cardiovasc Interv 687 2019;**12**:1328–38. doi:10.1016/j.jcin.2019.06.013 688 44 Wojnarski CM, Roselli EE, Idrees JJ, et al. Machine-learning phenotypic classification of 689 bicuspid aortopathy. The Journal of Thoracic and Cardiovascular Surgery 2018;155:461-469.e4. 690 doi:10.1016/j.jtcvs.2017.08.123

691 45 Chen Z, Li J, Sun Y, et al. A novel predictive model for poor in-hospital outcomes in patients 692 with acute kidney injury after cardiac surgery. The Journal of Thoracic and Cardiovascular Surgery 693 Published Online First: 11 May 2021. doi:10.1016/j.jtcvs.2021.04.085 694 46 Domaratzki M, Kidane B. Deus ex machina? Demystifying rather than deifying machine 695 learning. The Journal of Thoracic and Cardiovascular Surgery 2022;163:1131-1137.e4. 696 doi:10.1016/j.jtcvs.2021.02.095 697 47 Rajkomar A, Dean J, Kohane I. Machine Learning in Medicine. *New England Journal of* 698 Medicine 2019;380:1347-58. doi:10.1056/NEJMra1814259 699 48 Finlayson SG, Subbaswamy A, Singh K, et al. The Clinician and Dataset Shift in Artificial 700 Intelligence. New England Journal of Medicine 2021;385:283-6. doi:10.1056/NEJMc2104626 701 49 Subbaswamy A, Saria S. From development to deployment: dataset shift, causality, and shift-702 stable models in health AI. Biostatistics 2020;21:345-52. doi:10.1093/biostatistics/kxz041 703 Duckworth C, Chmiel FP, Burns DK, et al. Using explainable machine learning to characterise 50 704 data drift and detect emergent health risks for emergency department admissions during COVID-705 19. Sci Rep 2021;11:23017. doi:10.1038/s41598-021-02481-y 706 Huang C, Li S-X, Caraballo C, et al. Performance Metrics for the Comparative Analysis of 51 707 Clinical Risk Prediction Models Employing Machine Learning. [Miscellaneous Article]. Circulation: 708 Cardiovascular Quality & Outcomes 2021;14. doi:10.1161/CIRCOUTCOMES.120.007526 709 52 Ericksen SS, Wu H, Zhang H, et al. Machine Learning Consensus Scoring Improves 710 Performance Across Targets in Structure-Based Virtual Screening. J Chem Inf Model 711 2017;57:1579-90. doi:10.1021/acs.jcim.7b00153 712 53 Hornik K, Meyer D. Deriving Consensus Rankings from Benchmarking Experiments. In: 713 Decker R, Lenz H-J, eds. Advances in Data Analysis. Berlin, Heidelberg: : Springer 2007. 163–70. 714 doi:10.1007/978-3-540-70981-7 19 715 54 Hu J, Peng Y, Lin Q, et al. An ensemble weighted average conservative multi-fidelity 716 surrogate modeling method for engineering optimization. Engineering with Computers Published 717 Online First: 9 November 2020. doi:10.1007/s00366-020-01203-8 718 55 Devaraj J, Madurai Elavarasan R, Pugazhendhi R, et al. Forecasting of COVID-19 cases using 719 deep learning models: Is it reliable and practically significant? *Results in Physics* 2021;21:103817. 720 doi:10.1016/j.rinp.2021.103817 721 56 Fudulu DP, Dimagli A, Sinha S, et al. Weekday and outcomes of elective cardiac surgery in 722 the UK: a large retrospective database analysis. Eur J Cardiothorac Surg 2022;:ezac038. 723 doi:10.1093/ejcts/ezac038 724 725

726 Figure legends

Figure 1. Design overview of the study; non-temporal performance and drift (temporal)

analyses are performed; drift in discrimination, calibration, clinical utility, dataset and

variable importance are assessed; time point assessments are performed for CEM; drifts in

component metrics of CEM are evaluated.

Figure 2. a) Plot of CEM by model and by year month; geometric mean of 1000 bootstraps at

each time point is shown as is 95% CI; horizontal line represents the CEM geometric mean of

all models; b) Box plot of difference in models' CEM across first three months of 2017 and

734 2019; Kruskal-Wallis results for CEM across the time points are shown; c) Paired samples

735 Wilcoxon test (Wilcoxon signed-rank test) for first 3 months of 2019 bootstrap CEM values;

p-values are adjusted using the bonferroni method.

Figure 3. Plot of CEM by model (a. Xgboost; b. Random Forest; c. Logistic Regression; d.

EuroSCORE II) and by year month; geometric mean of 1000 bootstraps at each time point is

shown; red dotted line shows linear regression; blue line shows Generalised Additive Model
 fit (GAM): parameters and p-value for linear regression are shown; e) Discrimination (AUC)

fit (GAM); parameters and p-value for linear regression are shown; e) Discrimination (AUC)
 performance drift by year month: linear regression lines are plotted for each model with slope.

performance drift by year month; linear regression lines are plotted for each model with slope,
 intercept and p-values displayed in legend; f) Calibration (adjusted ECE) performance drift

intercept and p-values displayed in legend; f) Calibration (adjusted ECE) performance drift
 by year month; linear regression lines are plotted for each model with slope, intercept and p-

values displayed in legend; SVM and ES II are removed to enable clearer separation of

745 models with similar performance.

Figure 4 a) Clinical effectiveness (net benefit) performance drift by year month; linear

regression lines are plotted for each model with slope, intercept and p-values displayed in

response to enable clearer separation of models with similar

performance; b) SHAP variable importance drift for 27 month of Holdout set; solid dots show

geometric mean values of 5 fold cross validation; smoothed loess lines are plotted, with green

bands showing 95% confidence intervals; c) SHAP variable importance drift for 27 month of

Holdout set for top six most important variables; trends are unsmoothed; d) Operative

rs3 urgency dataset drift across year month for Holdout set; percentages of each category are

shown for each time point.

755

756

757 758 759

760

761

762

763	
764	
765	
766	
767	
768	
769	
770	
771	
772	
773	
774	
775	
776	
777	
778	Table 1. Patient Demographics

# 779 **Table 1.** Summary of cleaned Euroscore II Variables. Variables are for the time period 2012 – 2019.

### 780 Records with missing mortality status were excluded.

	y Status	•	
Variable	1, N = 6,258 <sup>1</sup>	p-value <sup>2</sup>	
Age (years), mean (SD)	67.53 (11.23)	70.77 (11.42)	<0.001

Mortality Status						
Variable	0, N = 220,829 <sup>1</sup>	1, N = 6,258 <sup>1</sup>	p-value <sup>2</sup>			
NYHA, n (%)			<0.001			
0 – 1	48,625 (22%)	1,055 (17%)				
1 – II	96,888 (44%)	1,609 (26%)				
2 – III	64,049 (29%)	2,228 (36%)				
3 – IV	11,267 (5.1%)	1,366 (22%)				
Renal impairment, n (%)			<0.001			
0 - Normal	103,196 (47%)	1,704 (27%)				
1 - Moderate	92,411 (42%)	2,451 (39%)				
2 - On Dialysis	2,187 (1.0%)	330 (5.3%)				
3 - Severe	23,035 (10%)	1,773 (28%)				
Chronic lung disease, n (%)	26,644 (12%)	1,211 (19%)	<0.001			
Poor mobility, n (%)	8,305 (3.8%)	514 (8.2%)	<0.001			
Previous cardiac surgery, n (%)	12,012 (5.4%)	1,141 (18%)	<0.001			
LV function			<0.001			
0 - Good (>50%)	184,721 (84%)	4,706 (75%)				
1 - Moderate (31-50%)	30,608 (14%)	1,089 (17%)				
2 - Poor (21-30%)	4,241 (1.9%)	318 (5.1%)				
3 - Very Poor (≤20%)	1,259 (0.6%)	145 (2.3%)				
Pulmonary hypertension, n (%)			<0.001			
0 – PA Systolic (<31mmHg)	201,643 (91%)	5,000 (80%)				
1 – PA Systolic (31-55 mmHg)	13,126 (5.9%)	705 (11%)				
2 – PA Systolic (>55mmHg)	6,060 (2.7%)	553 (8.8%)				
CCS class 4 angina, n (%)	18,370 (8.3%)	956 (15%)	<0.001			
Urgency, n (%)			<0.001			
0 - Elective	141,617 (64%)	2,442 (39%)				
1 - Urgent	72,090 (33%)	2,134 (34%)				
2 - Emergency	6,533 (3.0%)	1,230 (20%)				
3 - Salvage	589 (0.3%)	452 (7.2%)				
Weight of the intervention, n (%)			<0.001			
0 – Isolated CABG	111,243 (50%)	1,546 (25%)				

	Mortality Status					
Variable	0, N = 220,829 <sup>1</sup>	1, N = $6,258^{1}$	p-value <sup>2</sup>			
1 – Single non-CABG	62,568 (28%)	2,153 (34%)				
2 – 2 Procedures	42,649 (19%)	2,108 (34%)				
3 – 3 Procedures	4,369 (2.0%)	451 (7.2%)				
Diabetes on insulin, n (%)	12,818 (5.8%)	453 (7.2%)	<0.001			
Female gender, n (%)	59,467 (27%)	2,328 (37%)	<0.001			
Recent myocardial infarct, n (%)	43,316 (20%)	1,594 (25%)	<0.001			
Critical preoperative state, n (%)	7,255 (3.3%)	1,382 (22%)	<0.001			
Extracardiac arteriopathy, n (%)	22,327 (10%)	1,215 (19%)	<0.001			
Active endocarditis, n (%)	5,816 (2.6%)	493 (7.9%)	<0.001			
Surgery on thoracic aorta, n (%)	9,070 (4.1%)	896 (14%)	<0.001			
Euroscore II, mean (SD)	0.03 (0.04)	0.12 (0.14)	<0.001			

<sup>1</sup>Mean (SD) or Frequency (%)

<sup>2</sup>Wilcoxon rank sum test; Pearson's Chi-squared test

781

782

783

# 784 Table 2. Geometric Mean of Individual metrics for each model in the Holdout set; CEM refers to Clinical

785 Effective Metric; Standard deviation and 95% CI are shown for CEM. 1000 bootstrap samples were used

to derive geometric mean of each metric; adjusted 1 - ECE and 1 - Brier score values are shown; net

787 benefit is average absolute overall benefit across all thresholds.

Model Category	1 - ECE	AUC	1 - Brier	F1	Net Benefit	CEM.Mean	CEM.sd	CEM.n	CEM lower Cl	CEM upper Cl
EuroSCORE	0.641	0.800	0.814	0.240	0.461	0.541	0.004	1000	0.540	0.541
LR	0.997	0.819	0.976	0.264	0.902	0.717	0.005	1000	0.717	0.717
NN	0.997	0.813	0.976	0.259	0.901	0.713	0.006	1000	0.713	0.714
RF	0.996	0.835	0.976	0.277	0.904	0.727	0.005	1000	0.727	0.728
Weighted SVM	0.775	0.819	0.916	0.257	0.685	0.634	0.005	1000	0.634	0.634
Xgboost	0.996	0.834	0.976	0.279	0.904	0.728	0.005	1000	0.728	0.729
788										
789										
790										
791										
792										
793										
794										
795										
796										
797										
798										
799										
800										
801										
802										
803										

804			
805			
806			
807			
808			

# 809 **Table 3.** Dunnett's test with Xgboost as control and the rest of the models as comparison; 95% family-

810 wise confidence level are shown as well as mean difference in CEM and p-values.

					95% Cl	
	Group 1	Group 2	CEM Difference (1-2)	P Value	Lower Bound	<b>Upper Bound</b>
	EuroSCORE II		-0.1876	< 2e-16***	-0.1881	-0.1870
	LR	Vahoost	-0.0110	< 2e-16***	-0.0116	-0.0105
	NN	(Control)	-0.0148	< 2e-16***	-0.0154	-0.0142
	RF	(control)	-0.0009	0.00039***	-0.0015	-0.0003
	Weighted SVM		-0.0941	< 2e-16***	-0.0947	-0.0935
811	Signif. codes: o '**	**' 0.001 '**' (	0.01 '*' 0.05 '.' 0.1' '			
812						
813						
814						
815						
010						
816						
017						
817						
818						
819						
820						
020						

821

822			
823			
824			
825			
826			
827			
828			